Andexanet alfa, Recombinant human coagulation Factor Xa

Specification

• Cat#: THP-0048
• Product Name: Andexanet alfa, Recombinant human coagulation Factor Xa
• Cas No: 1262449-58-0
• Description: The product is a recombinant human coagulation Factor Xa that promotes blood coagulation. The product works by binding to Factor Xa inhibitors and prevent them from interacting with endogenous Factor Xa. The product retains the structural similarity to that of endogenous human factor Xa, but exists in its mature functional form without the need for activation via the intrinsic or extrinsic coagulation pathways and remains catalytically inactive due to structural modification. The procoagulation potential of the product is eliminated through the removal of a 34-residue fragment containing Gla: via this truncation, it is unable to bind to membrane surfaces and assemble the prothrombinase complex. It also prevents the product from taking up space on phospholipid surface membranes, so that native FXa may bind and assemble the prothrominase complex. The amino acid residue modification from serine to alanine in the binding site of the catalytic domain allows more effective binding to FXa inhibitors and deters it from converting prothrombin to thrombin.
• Sequences: ANSFLFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLERRKRRKRIVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDAGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK
• Species: Human
• Molecular Weight: Not Available
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: Not Available
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
• Application: The product is indicated for patients treated with Rivaroxaban and Apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. The product has not been shown to be effective for, and is not indicated for, the treatment of bleeding related to any Factor Xa inhibitors other than apixaban and rivaroxaban.
• Concentration: 100 mg/10mL

Pharmaceutical Information

• Pharmaceutical Application: Andexanet alfa
• Targets: Target 1. Tissue factor pathway inhibitor